To test this hypothesis, we first employed BT474 cells, a human breast cancer ERBB2-overexpressing cell line, which expresses ERBB4 at intermediate/high levels (Supplementary Figure S2B). The gene discussed is ERBB4; the disease is breast carcinoma.